Stem Cell Stocks 2012 - Biotech Stocks

http://blackberrystocks.com

November 11, 2011 - Looking for a Stem Cell Stock to Buy in 2012? Check out Aastrom Biosciences, Inc. (ASTM) which is due to present data on Monday at the American Heart Association. Adam Feurerstein recently highlighted Aastrom Biosciences, Inc. (ASTM) as a stock to watch going into 2012.

As for the stock, ASTM is in a nice uptrend but will have resistance at $2.99. If ASTM can close above $2.99, is has the chance to rally up into the mid to high $3's.

http://www.thestreet.com/_yahoo/video/11307642/the-next-big-thing-in-biotech-aastrom.html?

More Stock News

BlackberryStocks.com

StocksToBuy.org - Stock Forum

Aastrom Biosciences ASTM FDA News - 6/18/09

Shares of Aastrom Biosciences, Inc. (ASTM) are Up 31% to $0.50 in pre market trading ( 6/18/09 ) on the following FDA news below. ASTM is a stem cell stock which trades on the Nasdaq stock exchange. Discuss ASTM

Discuss Stocks - http://stockstobuy.org

FDA Allows Aastrom Biosciences to resume Heart Study

FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial

Patient Death Unrelated to Aastrom's CRCs; Trial to Resume At All Clinical Sites for Patients Suffering From Dilated Cardiomyopathy

June 18, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported that the U.S. Food and Drug Administration (FDA) has removed the clinical hold from the Company's U.S. Phase II IMPACT-DCM clinical trial and that patient enrollment would resume at all five initiated clinical sites. The IMPACT-DCM trial is evaluating the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient's own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure.

On June 17, 2009, the FDA informed Aastrom that it had completed its investigation into the death of a patient following treatment with the Company's CRCs and that the clinical hold had been lifted; therefore, the IMPACT-DCM clinical trial could resume. Based on autopsy results and medical records, the FDA, the clinical site's principal investigator and an independent Data Safety Monitoring Board (DSMB) have attributed the patient death to progression of the disease and determined it was unrelated to the CRC treatment.

"Patient safety is top priority for Aastrom. We are saddened by the loss of one of our patients. At the same time, we are grateful that this investigation was conducted in an efficient manner and that the FDA was able to provide prompt review and remove the clinical hold so quickly. This comprehensive review, along with the FDA's permission to carry on the trial without modifications, underscores the safety of the trial design and that our CRC product played no role in the patient's death," stated George W. Dunbar, President and Chief Executive Officer at Aastrom. "We do not expect that this short delay will interfere with our goal of completing patient enrollment in this trial by the end of calendar year 2009. We are eager to resume patient enrollment and treatment in the IMPACT-DCM trial and to continue evaluating the clinical data we gather from these patients." Full Article


For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE

Stem Cell Stocks 3/9/09 March 9, 2009

The following Stem Cell stocks will be higher today due to the decision from Barack Obama to overturn the block on government funding for embryonic stem cell research. White House officials said Sunday that the president's order will give the National Institutes of Health 120 days to develop ethical guidelines for the research.


Stem Cell Stocks March 9, 2009 - Pre Market

Stem Cells ( STEM ) - $2.21 Up 60.14%
Geron ( GERN ) - $5.10 Up 31.78%
Aastrom Biosciences ( ASTM ) - $0.63 Up 90.91%
Pluristem Therapeutics (PSTI) - $1.23 Up 15%
Opexa Theraputics ( OPXA ) - $0.55 Up 83.33%
Thermogenesis ( KOOL ) - $0.60 Up 49.25%
Cytori Therapeutics ( CYTX ) - $3.30 Up 42.86%

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Baltic Dry Index

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Hot Penny Stocks 1/23/09 January 23, 2009

Today, 1/23/09, there are several penny stock gainers breaking out to the upside. Be sure to check out the Top 2009 Penny Stock Gainers on the NYSE, Nasdaq, and AMEX.


Penny Stock Gainers - January 23, 2009

Aastrom Biosciences ( ASTM ) - $0.66 Up 28.01% - ASTM is continuing to go from from yesterday due to the GERN stem cell news.

Thermogenesis (KOOL) - $0.68 Up 28.05% - KOOL is going up due to the Geron news as well - KOOL is a stem cell stock.

Northgate Minerals ( NXG ) - $1.19 Up 13.33% - Rimfire and Northgate Report Drilling at Boulevard Property Yields Gold Mineralization

Check out the biggest stock gainers today.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Geron GERN Stem Cell Stocks 1/23/09

Geron ( GERN ) is out with Stem Cell news this morning, January 23, 2009 - as this company will be the first company testing a human in the world's first human clinical trial involving Stem Cells. Under the new Obama administration, the FDA has approved this trial in which the Bush administration wasn't allowing Government funding for Stem Cell Research.

GERN stock is exploding higher today, to $6.48 Up 24%. Other Stem Cell stocks are higher such as Stem Cells ( STEM ) and Aastrom Biosciences ( ASTM )

Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The clearance enables Geron to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.

"The FDA's clearance of our GRNOPC1 IND is one of Geron's most significant accomplishments to date," said Thomas Okarma, Ph.D., M.D., Geron's president and CEO. "This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."

GRNOPC1, Geron's lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).

"The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury," said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. "Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year."

Full Article - http://www.geron.com/media/pressview.aspx?id=863

For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE